HC Wainwright restated their buy rating on shares of INmune Bio (NASDAQ:INMB) in a research report report published on Thursday morning, AnalystRatings.com reports. HC Wainwright currently has a $11.50 target price on the stock.

“We maintain our Buy rating of INMB and our 12-month price target of $11.50 per share. We derive our price target based on a risk-adjusted net present value (rNPV) analysis of projected future revenues from 2030, assuming a 13% discount rate and a 0.5% terminal growth rate. We derive an rNPV of $345M for the products and add in cash and cash equivalents of $9.4M to arrive at a 12-month price target of $11.43 per diluted share, which we round to $11.50.”,” HC Wainwright’s analyst wrote.

Separately, Maxim Group restated a buy rating and issued a $13.00 target price on shares of INmune Bio in a report on Wednesday, August 14th.

Shares of INmune Bio stock remained flat at $$6.20 on Thursday. 5,587 shares of the stock traded hands, compared to its average volume of 20,736. The company has a debt-to-equity ratio of 0.01, a quick ratio of 20.94 and a current ratio of 20.94. INmune Bio has a 1 year low of $5.06 and a 1 year high of $11.50. The firm has a 50 day moving average of $6.95 and a 200-day moving average of $8.83.

INmune Bio (NASDAQ:INMB) last issued its earnings results on Monday, August 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.16. As a group, equities research analysts forecast that INmune Bio will post -0.65 earnings per share for the current fiscal year.

In related news, Director Scott Juda purchased 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 21st. The shares were acquired at an average price of $6.00 per share, for a total transaction of $30,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders purchased 12,000 shares of company stock worth $72,990. 67.67% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in INmune Bio stock. BlackRock Inc. boosted its stake in INmune Bio Inc (NASDAQ:INMB) by 1,556.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,048 shares of the company’s stock after acquiring an additional 2,864 shares during the period. BlackRock Inc.’s holdings in INmune Bio were worth $29,000 at the end of the most recent reporting period. 0.36% of the stock is owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

Recommended Story: What are municipal bonds?

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.